Galactica Biotech Overview

  • Founded
  • 2014
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Latest Deal Amount
  • $97.4K
Latest Deal Amount
  • Investors
  • 2

Galactica Biotech General Information


Operator of drug development platform created to set new standards in the pharmaceutical industry adding value to drugs and contributing to the health of people. The company's drug development platform utilizes advanced analytical methods including artificial intelligence and machine learning to identify new uses for molecules, it provides a drug repurposing method to identify novel applications for molecules in the market and in the development of major and orphan diseases, enabling patients to reduced risk and companies to save time and cost.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Cork
  • Ireland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Galactica Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 10-May-2017 $97.4K 000.00 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2015 00000 Completed Startup
To view Galactica Biotech’s complete valuation and funding history, request access »

Galactica Biotech Executive Team (4)

Name Title Board Seat Contact Info
Jorge Valencia Co-Founder & Chief Executive Officer
Karen Dunn Co-Founder & Chief Scientific Officer
Alina Valencia Co-Founder & Director of Business
Javier Caballero Co-Founder
To view Galactica Biotech’s complete executive team members history, request access »

Galactica Biotech Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
RebelBio Accelerator/Incubator Minority 000 0000 000000 0
OneStart Accelerator/Incubator 000 0000 000000 0
To view Galactica Biotech’s complete investors history, request access »